The advanced lung cancer inflammation index, an index that combines body weight, albumin and neutrophil to lymphocyte ratio (NLR), was originally used to assess systemic inflammation levels in cancer patients (Jafri et al., 2013). This evidence concerns the gene ALB and lung cancer.